

Product datasheet for **TR310489**

PEX7 Human shRNA Plasmid Kit (Locus ID 5191)

Product data:

Product Type:	shRNA Plasmids
Product Name:	PEX7 Human shRNA Plasmid Kit (Locus ID 5191)
Locus ID:	5191
Synonyms:	PBD9B; PTS2R; RCDP1; RD
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	PEX7 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 5191). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	NM_000288 , NM_000288.1 , NM_000288.2 , BC006268 , BC006268.1 , BC031606 , NM_000288.4
UniProt ID:	O00628
Summary:	This gene encodes the cytosolic receptor for the set of peroxisomal matrix enzymes targeted to the organelle by the peroxisome targeting signal 2 (PTS2). Defects in this gene cause peroxisome biogenesis disorders (PBDs), which are characterized by multiple defects in peroxisome function. There are at least 14 complementation groups for PBDs, with more than one phenotype being observed in cases falling into particular complementation groups. Although the clinical features of PBD patients vary, cells from all PBD patients exhibit a defect in the import of one or more classes of peroxisomal matrix proteins into the organelle. Defects in this gene have been associated with PBD complementation group 11 (PBD-CG11) disorders, rhizomelic chondrodysplasia punctata type 1 (RCDP1), and Refsum disease (RD). [provided by RefSeq, Oct 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).